ONCIMMUNE HLDNGS LS-01
Oncimmune Holdings plc, a precision medicine company, provides autoantibody biomarker profiling in immuno-oncology, autoimmune, and infectious diseases in Europe and internationally. The company offers ImmunoINSIGHTS platform, an autoantibody profiling service that provides insights to discover and validate novel biomarkers, validate drug mode of action, improve treatment responses and adverse ev… Read more
ONCIMMUNE HLDNGS LS-01 (OCY) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, ONCIMMUNE HLDNGS LS-01 (OCY) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
ONCIMMUNE HLDNGS LS-01 - Net Assets Trend (None–None)
This chart illustrates how ONCIMMUNE HLDNGS LS-01's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ONCIMMUNE HLDNGS LS-01 (None–None)
The table below shows the annual net assets of ONCIMMUNE HLDNGS LS-01 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to ONCIMMUNE HLDNGS LS-01's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
ONCIMMUNE HLDNGS LS-01 Competitors by Market Cap
The table below lists competitors of ONCIMMUNE HLDNGS LS-01 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Roth CH Acquisition V Co. Warrant
NASDAQ:ROCLW
|
$470.01K |
|
Fictor Alimentos S.A.
SA:FICT3
|
$470.31K |
|
Chokwang Leather Co. Ltd.
KQ:004700
|
$470.56K |
|
OCCID.PETROL CORP - Dusseldorf Stock Exchang
DU:OPC
|
$471.18K |
|
Rising Stone S.A.
PA:ALRIS
|
$469.28K |
|
KON.VOPAK NV (VPK5.SG)
STU:VPK5
|
$469.16K |
|
Coala Life Group AB
ST:COALA
|
$468.93K |
|
Quicklizard Ltd
TA:QLRD
|
$468.63K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ONCIMMUNE HLDNGS LS-01's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares ONCIMMUNE HLDNGS LS-01's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently ONCIMMUNE HLDNGS LS-01 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares ONCIMMUNE HLDNGS LS-01's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ONCIMMUNE HLDNGS LS-01 (OCY) | €- | N/A | N/A | $469.69K |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |